Clinical Trial Update: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

This Phase 2 pediatric MATCH trial update reports results for tazemetostat in patients with relapsed or refractory solid tumors, non-Hodgkin lymphoma, or histio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Langerhans Cell Histiocytosis
• Non-hodgkin Lymphoma
• Soft Tissue Sarcoma

Drugs mentioned

• TAZVERIK (TAZEMETOSTAT)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-04-27